The GTPase switch is a versatile molecular device used by many proteins, such as the small GTPases, to regulate an astounding number of functions. Although the basics of the guanine nucleotide cycle ...

Scientists at the University of California, San Francisco (UCSF), have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases—from Parkinson’s ...

The GTPase Arl3p is required to recruit a second GTPase, Arl1p, to the Golgi in Saccharomyces cerevisiae. Arl1p binds to the GRIP domain, which is present in a number of long coiled-coil proteins or ...

The GTPases constitute a very large protein family, whose members are involved in the control of cell growth, transport of molecules, synthesis of other proteins, etc. Despite the many functions of ...

UCSF scientists have discovered how to target a large family of molecular switches called GTPases that are involved in myriad diseases, from Parkinson’s to cancer, and have long been thought to be ...

The Transcreener GTPase Assay Kit relies on direct detection of GDP produced by GTPases during GTP hydrolysis. The direct detection approach is a novel method to quantify activity of GTPases and their ...

Drugs for the K-Ras oncogene inspire an approach for targeting the GTPases, a family of enzymes whose dysfunction can lead to Parkinson's and many other diseases. UCSF scientists have discovered how ...

Astellas Pharma Inc. has divulged proteolysis targeting chimera (PROTAC) compounds acting as GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer ...

Although there are more than 150 guanosine triphosphate (GTP)–binding proteins, or GTPases, only the GTPase KRas G12C has proved susceptible to small-molecule drugs. That’s because it’s tough to find ...

GPCRs are by far the most extensively validated class of therapeutic targets, and there remains tremendous potential for targeting new receptors and their downstream effectors. GPCRs at the cell ...

Scientists have discovered how to target a class of molecular switches called GTPases that are involved in a myriad of diseases from Parkinson's to cancer and have long been thought to be 'undruggable ...